AMD therapies in Phase II


What therapies have made it to Phase II clinical trials?



ATG3 (CoMentis, formerly Athenagen): Nicotinic acetylcholine antagonist

ATG3 is a proprietary topical ophthalmic formulation of mecemylamine, an antagonist of the nicotinic acetylocholine receptor pathway that mediates angiogenesis, under investigation for the treatment of wet AMD.

CoMentis has initiated a Phase II study that will enrol 330 subjects to be randomized into one of three treatment groups: two different doses of ATG3 administered by eye drop twice daily, or placebo. All subjects will be monitored over a 48-week period to assess the drug' safety, tolerability and efficacy.

TG100801 (TargeGen): Anti-VEGF

TG100801 is administered non-invasively as an eye drop and is designed to suppress VEGF-mediated leakage and additional kinase targets associated with inflammation, edema and angiogenesis.

TargeGen recently initiated a multicentre Phase II clinical trial of TG100801 in patients with AMD.

Recent Videos
Durga Borkar, MD, MMCi, discusses FAS inhibition with ONL-1204
Theodore Leng, MD, MS, speaks about 12-Month Real-World Clinical and Anatomical Outcomes With Faricimab in Patients With Diabetic Macular Edema:The FARETINA-DME Study
Rishi P. Singh, MD, discussed his presentation on the results from part 1 of the Phase 2/3 SIGLEC trial assessing AVD-104 for GA
Carl C. Awh, MD, FASRS, speaks with Hattie Hayes of Ophthalmology Times Europe
Carl J. Danzig, MD
Martin Zinkernagel, MD, PhD, speaks about the ASRS sustainability expert panel
Srinivas Sai Kondapalli, MD, discusses outer retinal tubulations in lesion growth for subfoveal and non-subfoveal GA
Jennifer I. Lim, MD, FARVO, FASRS
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
© 2024 MJH Life Sciences

All rights reserved.